Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie最新文献

筛选
英文 中文
Extracellular vesicles in viral myocarditis: Mechanisms, biomarkers and emerging therapeutic strategies. 病毒性心肌炎的细胞外囊泡:机制、生物标志物和新兴治疗策略。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-14 DOI: 10.1016/j.biopha.2026.120059
Amirhossein Bahreyni, Honglin Luo
{"title":"Extracellular vesicles in viral myocarditis: Mechanisms, biomarkers and emerging therapeutic strategies.","authors":"Amirhossein Bahreyni, Honglin Luo","doi":"10.1016/j.biopha.2026.120059","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120059","url":null,"abstract":"<p><p>Viral myocarditis (VM) is an inflammatory heart disease most commonly triggered by viral infection and represents a major cause of acute cardiac dysfunction and chronic inflammatory cardiomyopathy. Although cardiomyocyte injury and immune activation are central to VM pathogenesis, the mechanisms by which viral infection coordinates intercellular communication to drive disease progression remain incompletely understood. Extracellular vesicles (EVs) have emerged as key mediators of cell-to-cell signaling, capable of transporting viral components and host-derived factors that modulate immune responses and cardiac function. In this review, we integrate preclinical and clinical evidence to define the mechanistic roles of EVs in VM and evaluate their translational potential. We highlight circulating EVs as minimally invasive biomarkers for early diagnosis and disease monitoring. We further discuss emerging strategies to therapeutically target or engineer EVs to modulate both viral replication and maladaptive host responses.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120059"},"PeriodicalIF":7.5,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
α-pinene and the central nervous system: Mechanistic insights, preclinical evidence, and translational perspectives. α-蒎烯和中枢神经系统:机制的见解,临床前证据和翻译的观点。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-14 DOI: 10.1016/j.biopha.2026.120057
Kaveh Rahimi, Akram Ebrahimifar
{"title":"α-pinene and the central nervous system: Mechanistic insights, preclinical evidence, and translational perspectives.","authors":"Kaveh Rahimi, Akram Ebrahimifar","doi":"10.1016/j.biopha.2026.120057","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120057","url":null,"abstract":"<p><strong>Background: </strong>α-Pinene is a naturally occurring monoterpene that has attracted increasing interest for its potential effects on the central nervous system (CNS). This review critically evaluates preclinical evidence regarding its effects on neuroinflammation, oxidative stress, neurotrophic signaling, cellular injury, and behavioral outcomes.</p><p><strong>Methods: </strong>A literature search was performed in PubMed, Scopus, Web of Science, and Google Scholar from database inception to April 2026. Studies investigating CNS-related effects of α-pinene, including in vitro and in vivo experimental studies, were narratively synthesized according to biological mechanisms, experimental models, doses, administration routes, treatment duration, and outcomes. No formal risk-of-bias assessment or quantitative meta-analysis was performed.</p><p><strong>Results: </strong>Preclinical evidence indicates that α-pinene is associated with attenuation of inflammatory signaling, particularly TLR4/MyD88/NF-κB-related responses, and reduction of oxidative stress accompanied by enhanced endogenous antioxidant defenses. Modulation of BDNF/TrkB/CREB-associated signaling has also been reported, although evidence is more limited and context-dependent. Additional studies suggest effects on apoptosis-related signaling, glial activation, inflammasome-associated pathways, JNK signaling, and endoplasmic reticulum stress. Behavioral studies report anxiolytic-like, cognitive, anticonvulsant, motor-protective, and analgesic effects in several experimental models. However, dose-response and pharmacokinetic-pharmacodynamic relationships remain insufficiently characterized, and some findings are model-dependent.</p><p><strong>Conclusion: </strong>Current evidence supports α-pinene as a biologically active monoterpene with CNS-related effects predominantly demonstrated in preclinical models. A single validated molecular mechanism, therapeutic dose range, or human CNS therapeutic window has not been established. Further independent replication, standardized dose-response studies, brain-exposure profiling, mechanistic validation, and long-term safety studies are required before clinical translation can be considered.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120057"},"PeriodicalIF":7.5,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Plasminogen Activator Inhibitor 1 (PAI-1) paradox in cancer: From tumor microenvironment remodeling to therapeutic targeting. 癌症中的纤溶酶原激活物抑制剂1 (PAI-1)悖论:从肿瘤微环境重塑到治疗靶向。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-12 DOI: 10.1016/j.biopha.2026.120055
Audrey Bennetot, Gilles Pagès, Maeva Dufies
{"title":"The Plasminogen Activator Inhibitor 1 (PAI-1) paradox in cancer: From tumor microenvironment remodeling to therapeutic targeting.","authors":"Audrey Bennetot, Gilles Pagès, Maeva Dufies","doi":"10.1016/j.biopha.2026.120055","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120055","url":null,"abstract":"<p><p>Plasminogen activator inhibitor-1 (PAI-1), encoded by the SERPINE1 gene, is a key regulator of the fibrinolytic system through inhibition of the plasminogen activators urokinase (uPA) and tissue-type plasminogen activator (tPA). Although this canonical function would be expected to limit extracellular matrix degradation and tumor invasion, elevated PAI-1 expression is consistently associated with tumor progression and poor clinical outcomes across multiple cancer types. This apparent contradiction, known as the \"PAI-1 paradox,\" highlights the diverse biological functions of PAI-1 beyond fibrinolysis. Within the tumor microenvironment, PAI-1 regulates several hallmarks of cancer through interactions with extracellular matrix components and receptors such as LRP1, uPAR, and integrins. These interactions influence angiogenesis, apoptosis resistance, tumor cell migration, and extracellular matrix remodeling. Emerging evidence also indicates that PAI-1 shapes the immune microenvironment by modulating immune cell recruitment and macrophage polarization, although the underlying mechanisms remain incompletely understood. Clinically, SERPINE1 overexpression correlates with poor prognosis in numerous malignancies, including colorectal, lung, breast, and gastric cancers. Pharmacological targeting of the PAI-1 axis with small-molecule inhibitors or neutralizing antibodies shows antitumor activity in preclinical models, and the oral inhibitor TM5614 has reached phase III clinical trial in chronic myeloid leukemia and melanoma. This narrative review summarizes current knowledge of PAI-1 regulation and function in cancer and discusses therapeutic strategies targeting this pathway.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120055"},"PeriodicalIF":7.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contribution of angiotensin receptor type II to dermal extravasation caused by bradykinin in mice: Implications for sartan-induced angioedema. 血管紧张素受体II型对小鼠缓激肽引起的皮肤外渗的贡献:沙坦诱导的血管性水肿的意义。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-12 DOI: 10.1016/j.biopha.2026.120056
Vu Thao-Vi Dao, Ehsan Fahimi, Marion Bisha, Thomas Kurz, Finn Kristian Hansen, Cansu Aközbek, Tatsiana Suvorava, Georg Kojda
{"title":"Contribution of angiotensin receptor type II to dermal extravasation caused by bradykinin in mice: Implications for sartan-induced angioedema.","authors":"Vu Thao-Vi Dao, Ehsan Fahimi, Marion Bisha, Thomas Kurz, Finn Kristian Hansen, Cansu Aközbek, Tatsiana Suvorava, Georg Kojda","doi":"10.1016/j.biopha.2026.120056","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120056","url":null,"abstract":"<p><strong>Background: </strong>While non-allergic angioedema induced by ACE inhibitors and sacubitril are caused by reduced bradykinin degradation and over-activation of bradykinin receptor type 2 (B2), the pathophysiology of sartan-induced angioedema is not fully understood. As angiotensin II receptor (AT) type 1 blockers (sartans) increase circulating angiotensin II, enhanced activation of AT2 by angiotensin II likely occurs. The aim of this study was to investigate whether the AT2 agonist compound 21 (C21) inhibits ACE activity and increases bradykinin-induced dermal extravasation.</p><p><strong>Methods: </strong>Increased plasma angiotensin II by telmisartan was measured at a dose that reduced systolic blood pressure by 20 mmHg. C21 was synthesized and its biological activity assessed by vasorelaxation of aortic rings of control mice which was absent in rings of AT2<sup>-/y</sup> mice. As for Miles Assays AT2<sup>-/y</sup> mice were backcrossed to C57BL/6 J (AT2<sup>-/y</sup>-C57). Blood pressure remained unchanged by C21.</p><p><strong>Results: </strong>In Miles assays in C57BL/6 J, but not in AT2<sup>-/y</sup>-C57, C21 potentiated dermal extravasation induced by bradykinin that was inhibited by the AT2 antagonist PD123319, while extravasation by the ACE resistant B2 agonist labradimil remained. Pre-treatment of human endothelial cells with C21 strongly reduced ACE activity in cell homogenates in an AT2 dependent manner suggesting a cellular loss of ACE and indicating reduced tissue ACE activity. Correspondingly, increased ACE activity in plasma occurred following treatment with C21.</p><p><strong>Conclusion: </strong>These data suggest an increase of bradykinin-induced skin extravasation due to direct AT2 activation which may contribute to explaining the molecular mechanism underlying the occurrence of sartan-induced non-allergic angioedema.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120056"},"PeriodicalIF":7.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum to characterizing ghrelin's role in dysregulating GLP-1-mediated function and promoting the development of alcohol-associated liver disease'[Journal Title: Biomed. Pharmacother. 195(2026) 118924]. 表征ghrelin在glp -1介导的功能失调和促进酒精相关肝脏疾病发展中的作用的勘误[期刊标题:Biomed]。药物学杂志[j]。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-12 DOI: 10.1016/j.biopha.2026.120037
Sundararajan Mahalingam, Ramesh Bellamkonda, Kusum K Kharbanda, Ojeshvi Ethiraj, Nagasundaram Nagarajan, Chittibabu Guda, Kanika Sharma, Micah B Schott, Carol A Casey, Lorenzo Leggio, Karuna Rasineni
{"title":"Erratum to characterizing ghrelin's role in dysregulating GLP-1-mediated function and promoting the development of alcohol-associated liver disease'[Journal Title: Biomed. Pharmacother. 195(2026) 118924].","authors":"Sundararajan Mahalingam, Ramesh Bellamkonda, Kusum K Kharbanda, Ojeshvi Ethiraj, Nagasundaram Nagarajan, Chittibabu Guda, Kanika Sharma, Micah B Schott, Carol A Casey, Lorenzo Leggio, Karuna Rasineni","doi":"10.1016/j.biopha.2026.120037","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120037","url":null,"abstract":"","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":" ","pages":"120037"},"PeriodicalIF":7.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formulation-controlled redaporfin cellular-targeted photodynamic therapy sensitizes tumors to PD-1/PD-L1 blockade via immunogenic cell death. 配方控制的reaporfin细胞靶向光动力疗法通过免疫原性细胞死亡使肿瘤对PD-1/PD-L1阻断敏感。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-12 DOI: 10.1016/j.biopha.2026.120054
Marta Warszyńska, Lilianna Szyk-Warszyńska, Dominik Barczyk, Paweł Repetowski, Joanna Kuncewicz, Janusz M Dąbrowski
{"title":"Formulation-controlled redaporfin cellular-targeted photodynamic therapy sensitizes tumors to PD-1/PD-L1 blockade via immunogenic cell death.","authors":"Marta Warszyńska, Lilianna Szyk-Warszyńska, Dominik Barczyk, Paweł Repetowski, Joanna Kuncewicz, Janusz M Dąbrowski","doi":"10.1016/j.biopha.2026.120054","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120054","url":null,"abstract":"<p><p>Redaporfin is a clinically advanced photosensitizer developed for vascular-targeted photodynamic therapy (V-PDT), yet its therapeutic utility under long drug-to-light interval, cellular-targeted PDT (C-PDT), remains limited despite substantial tumor exposure. Here, we show that formulation-dependent control of redaporfin photochemistry and ER-associated intracellular localization can convert otherwise non-curative C-PDT into an effective partner for immune checkpoint blockade. Encapsulation in Pluronic®-based micelles prolonged the redaporfin triplet-state lifetime over sevenfold relative to ethanol and over twentyfold relative to a non-micellar aqueous environment, while preserving oxygen accessibility. Direct comparison with Pluronic® F127 demonstrated carrier-specific effects: despite greater cell-free ROS generation, F127 showed lower encapsulation efficiency, poorer storage stability, and inferior intracellular ROS generation and phototoxicity. P123 enhanced ER-associated redaporfin accumulation at 24 h and amplified an ICD phenotype, evidenced by increased calreticulin exposure and HMGB1 release; P123-mediated C-PDT also activated macrophages with an M1-like marker profile and induced adaptive PD-L1 upregulation in surviving CT26 cells. In vivo fluorescence imaging confirmed rapid tumor accumulation and sustained retention of redaporfin/P123 at 24 h. Whereas C-PDT alone and α-PD-L1 monotherapy were non-curative, combination with PD-1 and/or PD-L1 blockade produced durable complete responses in up to 50% of mice. All complete responders remained tumor-free during 120-day follow-up, and dual blockade conferred protection against CT26 rechallenge, providing functional evidence of long-term antitumor immune memory. These findings establish formulation-driven control of intracellular photochemistry and subcellular localization as an underappreciated determinant of PDT-mediated anticancer immunity and provide a translational strategy for repurposing a clinically advanced V-PDT photosensitizer for durable photodynamic immunotherapy.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120054"},"PeriodicalIF":7.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactiplantibacillus plantarum alleviates Parkinson's disease progression by reducing enteroendocrine α-synuclein aggregation in a rotenone-induced mouse model. 在鱼藤酮诱导的小鼠模型中,植物乳杆菌通过减少肠内分泌α-突触核蛋白聚集来缓解帕金森病的进展。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-12 DOI: 10.1016/j.biopha.2026.120007
Fu-Sheng Deng, Yu-Fen Lin, Wei-Hsiang Chen, Tzu-Fun Fu, Ching-Ting Lin, Chien-Chen Wu, Ying-Chieh Tsai
{"title":"Lactiplantibacillus plantarum alleviates Parkinson's disease progression by reducing enteroendocrine α-synuclein aggregation in a rotenone-induced mouse model.","authors":"Fu-Sheng Deng, Yu-Fen Lin, Wei-Hsiang Chen, Tzu-Fun Fu, Ching-Ting Lin, Chien-Chen Wu, Ying-Chieh Tsai","doi":"10.1016/j.biopha.2026.120007","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120007","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder driven by α-synuclein (α-syn) aggregation and accumulation. Recent evidence suggests that gut dysbiosis may trigger α-syn accumulation in the enteric nervous system, which spreads to the brain via the vagus nerve. Restoring the gut microbial balance through probiotic intervention offers a promising strategy to mitigate gut-origin pathology in PD. Lactiplantibacillus plantarum PS128 (PS128), a probiotic strain with neuroprotective properties, has shown neurotherapeutic benefits in PD models and patients; however, its mechanisms remain unclear. In a rotenone-induced PD mouse model, we found that PS128 supplementation significantly improved motor deficits and gastrointestinal dysfunction, reversed enteroendocrine cell (EEC) hyperplasia in the proximal colon (PC), and reduced α-syn accumulation in both intestinal and brain tissues. Notably, phosphorylated α-syn levels were significantly elevated in EECs, the myenteric plexus, and the substantia nigra, and these elevations were reversed by PS128. Furthermore, using real-time calcium imaging in a zebrafish model, we demonstrated that PS128 directly activates EECs. Transcriptomic profiling of the PC revealed calcium signaling and vitamin D metabolism as the major pathways modulated by PS128. Consistent with the transcriptomic findings, biochemical analyses demonstrated that PS128 increased serum calcium and 25-hydroxyvitamin D levels. Moreover, 16S rRNA sequencing and correlation analysis revealed that PS128 modulated gut microbiota composition in PD-like mice, with changes in specific taxa correlating with α-syn burden and calcium regulation. Taken together, our findings suggest that PS128 alleviates PD-like pathology through modulation of the gut-brain axis and provide mechanistic insights into the neuroprotective actions of probiotics.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120007"},"PeriodicalIF":7.5,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The IgM- and IgA-enriched immunoglobulin preparation trimodulin suppresses neutrophil extracellular trap formation more effectively in vitro than standard intravenous immunoglobulin. IgM和iga富集的免疫球蛋白制剂trimodulin在体外比标准静脉注射免疫球蛋白更有效地抑制中性粒细胞胞外陷阱的形成。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-11 DOI: 10.1016/j.biopha.2026.120049
Rico Zapf, Gabriel Richter, Sandra Loskarn, Antonio Maccataio, Georg Schett, Fabian Bohländer, Ulrike Steffen
{"title":"The IgM- and IgA-enriched immunoglobulin preparation trimodulin suppresses neutrophil extracellular trap formation more effectively in vitro than standard intravenous immunoglobulin.","authors":"Rico Zapf, Gabriel Richter, Sandra Loskarn, Antonio Maccataio, Georg Schett, Fabian Bohländer, Ulrike Steffen","doi":"10.1016/j.biopha.2026.120049","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120049","url":null,"abstract":"<p><p>Neutrophil extracellular traps (NETs) represent an important mechanism of defense against pathogens. However, in cases of severe lung infection or sepsis, excessive NET formation has been observed to cause vascular occlusion, inflammation, and tissue damage. Treatment with intravenous immunoglobulins (IVIg), especially those enriched for IgA and IgM, has been shown to improve outcomes in patients with these conditions. We compared trimodulin, a novel polyvalent antibody preparation containing elevated levels of IgM (∼23%) and IgA (∼21%), with standard IVIg to determine their ability to reduce NET formation in vitro. Trimodulin strongly reduced NET formation by neutrophils stimulated with phorbol 12-myristate 13-acetate (PMA), complexed IgA, or complexed IgG. This effect was accompanied by reduced IL-8 secretion. Standard IVIg showed no significant effect. Dissecting trimodulin into its individual immunoglobulin components revealed that IgM has the strongest capacity to reduce NET formation, followed by IgG. Nevertheless, the combined additive effects of the individual immunoglobulins were less effective than trimodulin, potentially caused by synergistic effects between the three immunoglobulin classes within trimodulin. Together, our data show that trimodulin is a more potent regulator of NET formation than the tested standard IVIg, mainly due to its IgM component. Therefore, trimodulin may be beneficial in conditions involving excessive NET formation.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120049"},"PeriodicalIF":7.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Elastin-based polypeptide-Fc fusion for extended subcutaneous exposure and sustained thrombopoietic activity. 基于弹性蛋白的多肽- fc融合用于延长皮下暴露和持续的血小板生成活性。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-11 DOI: 10.1016/j.biopha.2026.120048
Cho Won Kim, Min-Jung Kim, Min Jeong Kang, Sung Su Yea, Hana Jung, Jihyung Han, Dong Woo Lim, SaeGwang Park, Jee-Yeong Jeong
{"title":"Elastin-based polypeptide-Fc fusion for extended subcutaneous exposure and sustained thrombopoietic activity.","authors":"Cho Won Kim, Min-Jung Kim, Min Jeong Kang, Sung Su Yea, Hana Jung, Jihyung Han, Dong Woo Lim, SaeGwang Park, Jee-Yeong Jeong","doi":"10.1016/j.biopha.2026.120048","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120048","url":null,"abstract":"<p><p>Immune thrombocytopenia is characterized by increased platelet destruction and impaired platelet production. Thrombopoietin receptor agonists (TPO-RAs) stimulate megakaryopoiesis, but the influence of elastin-based polypeptide (EBP) length on the hydrodynamic properties and platelet responses of Fc-fused TPO-RAs remains unclear. We generated three EBP-Fc fusion TPO-RAs-NT-202 G3, G6, and G12-and evaluated their physicochemical properties, biological activity, and platelet responses; G12 was also examined in an exploratory pharmacokinetic study. The variants, produced in Expi293 cells, differed only in EBP length; all remained soluble at 37°C in phosphate-buffered saline, and hydrodynamic size increased with EBP length. Binding was detected in BaF3/hMPL cells expressing the human thrombopoietin receptor but was minimal in parental BaF3 cells. The variants induced M-07e cell proliferation, JAK2-STAT signaling, and megakaryocytic differentiation of human CD34<sup>+</sup> cells. After a single subcutaneous dose of 500 µg/kg in normal mice, platelet elevation persisted longest with NT-202 G12. At 2000 µg/kg, NT-202 G12 peaked at 72 h and remained quantifiable through 336 h. Because the pharmacokinetic study lacked an intravenous arm, used a different dose from the platelet-response studies, and relied on composite mean profiles, it was interpreted descriptively and could not distinguish absorption from elimination or establish an exposure-response relationship. In an anti-CD41 antibody-induced acute thrombocytopenia model, NT-202 G12 and romiplostim, an Fc-peptide TPO-RA, increased platelet counts without a significant between-group difference on day 9. Overall, this exploratory proof-of-concept study suggests that EBP block length is a genetically encoded design variable associated with hydrodynamic size and platelet-response duration.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120048"},"PeriodicalIF":7.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic-translational control of NK cell fitness under chronic stress. 慢性应激下NK细胞适应度的代谢-翻译控制。
IF 7.5
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2026-11-11 DOI: 10.1016/j.biopha.2026.120051
Beulah Favour Ortutu, Xinlei Guo, Christina James Thomas, Rashi Sharma, Carly Shaw Song, Kaylee Delgado, Kamlesh Sawant, Jianxun Song
{"title":"Metabolic-translational control of NK cell fitness under chronic stress.","authors":"Beulah Favour Ortutu, Xinlei Guo, Christina James Thomas, Rashi Sharma, Carly Shaw Song, Kaylee Delgado, Kamlesh Sawant, Jianxun Song","doi":"10.1016/j.biopha.2026.120051","DOIUrl":"https://doi.org/10.1016/j.biopha.2026.120051","url":null,"abstract":"<p><p>Natural killer (NK) cells are critical mediators of immune surveillance, yet their functional capacity is frequently compromised by chronic metabolic and environmental stress. Although metabolic reprogramming is recognized as a major determinant of NK-cell activity, how metabolic capacity is coordinated with translational control to sustain effector function and cellular persistence remains poorly understood. This review examines NK-cell fitness as a dynamic metabolic-translational balance in which nutrient availability, mitochondrial function, redox homeostasis, and nutrient-sensing pathways determine the resources available for biosynthesis, while translational control regulates their allocation toward effector protein production, adaptation, and cellular maintenance. We highlight eukaryotic elongation factor-2 kinase (eEF2K) as a mechanistically defined regulator of translational elongation with direct evidence of relevance to NK-cell function, while Nucleus Accumbens-Associated Protein 1 (NAC1) is considered a candidate regulator of NK-cell metabolic adaptation whose role remains to be established. We propose that the interaction between metabolic capacity and translational demand may determine whether NK cells maintain function or become dysfunctional under persistent stress. This framework provides a rationale for engineering NK cells with greater metabolic-translational reserve and resilience to metabolically restrictive tumor microenvironments, with potential implications for improving the persistence and therapeutic efficacy of adoptive and CAR-NK cell therapies.</p>","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"205 ","pages":"120051"},"PeriodicalIF":7.5,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书